Oncolytic Adenovirus Expressing a p53 Variant Resistant to Degradation by HPV E6 Protein Exhibits Potent and Selective Replication in Cervical Cancer

Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol., 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Munoz, 2003, Epidemiologic classification of human papillomavirus types associated with cervical cancer, N. Engl. J. Med., 348, 518, 10.1056/NEJMoa021641 von Knebel Doeberitz, 1988, Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells, Cancer Res., 48, 3780 Dyson, 1989, The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product, Science, 243, 934, 10.1126/science.2537532 Scheffner, 1990, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 Prendiville, 2003, LLETZ: theoretical rationale, practical aspects, clinical experience, optimizing the technique Heise, 2000, Replication-selective adenoviruses as oncolytic agents, J. Clin. Invest., 105, 847, 10.1172/JCI9762 Alemany, 2000, Replicative adenoviruses for cancer therapy, Nat. Biotechnol., 18, 723, 10.1038/77283 Oosterhoff, 2004, Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy, J. Exp. Ther. Oncol., 4, 37 Balague, 2001, Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes, J. Virol., 75, 7602, 10.1128/JVI.75.16.7602-7611.2001 Heise, 2000, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy, Nat. Med., 6, 1134, 10.1038/80474 Fueyo, 2000, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo, Oncogene, 19, 2, 10.1038/sj.onc.1203251 van Beusechem, 2002, Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency, Cancer Res., 62, 6165 Geoerger, 2004, Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma, Cancer Res., 64, 5753, 10.1158/0008-5472.CAN-04-0499 Geoerger, 2005, Expression of p53, or targeting towards EGFR enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma, Cancer Res., 7, 584 Hengstermann, 2001, Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells, Proc. Natl. Acad. Sci. USA, 98, 1218, 10.1073/pnas.98.3.1218 Scheffner, 1991, The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines, Proc. Natl. Acad. Sci. USA, 88, 5523, 10.1073/pnas.88.13.5523 Ferreux, 2003, Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus, J. Pathol., 201, 109, 10.1002/path.1394 van Houten, 2001, Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas, Int. J. Cancer, 93, 232, 10.1002/ijc.1313 Steenbergen, 1998, Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of human papillomavirus type 16- and 18-transfected human keratinocytes, J. Virol., 72, 749, 10.1128/JVI.72.1.749-757.1998 Koutsky, 2002, A controlled trial of a human papillomavirus type 16 vaccine, N. Engl. J. Med., 347, 1645, 10.1056/NEJMoa020586 Harper, 2004, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet, 364, 1757, 10.1016/S0140-6736(04)17398-4 Huang, 2003, A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine, Cancer Res., 63, 7321 Steenbergen, 1996, Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q, Oncogene, 13, 1249 Fallaux, 1996, Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors, Hum. Gene Ther., 7, 215, 10.1089/hum.1996.7.2-215 el-Deiry, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-P Kessis, 1993, Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage, Proc. Natl. Acad. Sci. USA, 90, 3988, 10.1073/pnas.90.9.3988